NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Agency / Source: NEC Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

NEC and NEC Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI - NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting - NEC-Bio.com
NEC and NEC Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI

 

NewswireTODAY - /newswire/ - Tokyo, Japan, 2024/11/07 - NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting - NEC-Bio.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

NEC Bio, NEC’s biotech branch, puts generative AI in practice and unveils successful modification of T cell receptors, a potential game changer in the world of TCR-based therapies.

Utilizing proprietary generative AI technology, NEC Bio has successfully modified T cell receptors (TCRs) to increase their efficacy. This achievement marks a major step forward in drug development and personalized medicine since prediction and engineering of TCR sequences that are able to bind to specific target sequences remains a major challenge in the field. The technology is being presented as a poster at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 6 to 10, 2024.

Advancing Personalized Cancer Treatment

NEC Bio’s mission is to develop groundbreaking therapies for patients around the globe using advanced cutting edge AI technologies. TCR-based therapies use the high binding affinity of TCR to bind to defined cancer cells and destruct them using various strategies. One major hurdle in the development of TCR therapies is the difficulty in identifying TCR sequences that will bind specifically to given target sequences. Conventionally, this involves a labor-intensive process of lab screening, trying to isolate the necessary TCR from human donor cells.

Motoo Nishihara, Corporate Executive Vice President and CTO of NEC, said: "We are incredibly proud to announce our work on T Cell Receptor engineering using our proprietary generative AI, presented at the Society for Immunotherapy of Cancer annual meeting. This initiative emphasizes our dedication to advancing immunotherapy and highlights the transformative potential of our technology. We are excited about the future and the significant impact our innovations will have on the field of cancer treatment. This technology makes our portfolio stronger and serves our mission to bring AI-led innovative medicine to patients globally."

About the technology

The AI model developed at NEC Bio utilizes generative AI and domain-specific large language models (LLMs) for creating novel TCRs with high efficacy. Given a target peptide, the AI model can generate high affinity TCR sequences for targeted therapy based on knowledge from machine learning on physio-chemical TCR interactions. The AI was benchmarked on public datasets and achieved better performance than baseline methods. The AI-designed TCRs were shown to have enhanced TCR activities in cell-based assays conducted in collaboration with Aichi Cancer Center.

Building on this success, NEC Bio will expand the application of its generative AI technology to design TCRs for various oncodriver targets, antibodies for specific targets, immunoproteins, DNA constructs, mRNA constructs, and more. This broad application spectrum highlights NEC Bio’s commitment to pushing the boundaries of what is possible in drug design and development.

SITC poster details

NEC Bio is presenting this technology in a poster at the Society for Immunotherapy of Cancer (SITC), in Houston, Texas, from November 6 to 10, 2024. Details on the poster are below:

Poster title: Design of Enhanced TCRs Against Cancer Antigens Using an AI System

Authors: Martin Renqiang Min, Tianxiao Li, Kazuhide Onoguchi, Daiki Mori, Jonathan Warrell, Pierre Machart, Anja Moesch, Andrea Meiser, Ivy Grace Pait, Ayako Okamura, Daisuke Muraoka, Hirokazu Matsushita, Kaidre Bendjama

Poster Number: 1230
Date: November 7, 2024
The poster can be found here: Home | NEC Bio B.V

About NEC Corporation

NEC Corporation (nec.com) has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.

About NEC Bio

NEC Bio (nec-bio.com), the biotech arm of NEC Corporation, is based in the Netherlands and dedicated to the development of innovative biotechnological solutions to tackle some of the most pressing health challenges. NEC Bio's research and development efforts are focused on creating personalized therapies that improve the quality of life for patients worldwide. NEC OncoImmunity in Oslo, Norway, is also a subsidiary of NEC Bio.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2024 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


NEC and NEC Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
NEC Bio |
Contact: Press Office - NEC.com 
+81 3-3454-1111 press[.]nec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Health / Surgery Most Recent Related Newswires:

Withings in Partnership with The French Government Invests €20.7M in Technical Innovation and AI to Propel Preventative Digital Healthcare
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment
LANXESS Unveils New Disinfectant to Counter Mpox Threat
VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test
Clinion Applauded by Frost & Sullivan for Enabling Interoperability and Continuity in Clinical Trials Management with its eClinical Solutions
GenieMD Awarded Frost & Sullivan’s 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions
Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming Remote Care Delivery with its Clinically Enabled, Patient-centric RPM
Greenway Health Earns Frost & Sullivan’s 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Prod
Verista Awarded by Frost & Sullivan for Providing Next-Generation Compliance and Quality Management Solutions in the Life Sciences Industry
TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and its Market-leading Position
Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases
Subang Jaya Medical Centre Awarded Frost & Sullivan’s Company of the Year Award for the Third Consecutive Year
Sunway Medical Centre Velocity Awarded by Frost & Sullivan for Leading the Malaysian Hospital Industry with Holistic Medical Care
George Clinical Applauded by Frost & Sullivan for its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific Region
AvantGuard Applauded by Frost & Sullivan for Extending the Life of Chlorine-based Disinfectants for Sustained Efficacy with its Residual Antimicrobial

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)